STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 01 February 2004 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for a Type I variation relating to the filling process, which will be carried out at an 
alternative  site  -  Sächsische  Serumwerke,  Dresden,  Germany.  The  EMEA  adopted  a  positive 
opinion  on  23  July  1997  and  no  amendments  to  the  Annexes  of  the  Community  Marketing 
Authorisation were required. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for a Type II variation relating to an additional presentation, where separate sterile 
needles are included with the pre-filled syringes (without needle). This new presentation applies 
to all package sizes. The EMEA adopted a positive opinion on 23 July 1997. The Commission 
Decision  amending  the  Community  Marketing  Authorisation  was  adopted  on  17  November 
1997. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for a Type I variation relating to the monograph, in which the set limit for unbound 
hepatitis A antigen has been modified in line with the performance of the ELISA used to test for 
the completeness of adsorption.  The EMEA adopted a positive opinion on 24 September 1997 
and no amendments to the Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application  for  a  Type  I  variation  relating  to  the  new  Manufacturing  Authorisation  Holder, 
SmithKline  Beecham  Biologicals  Manufacturing  S.A,  located  in  Wavre  Belgium,  which 
performs labelling  and packaging of the medicinal product. The  EMEA notified the European 
Commission and the MAH on 31 October 1997 that the variation is accepted. 
The  MAH  submitted  in  accordance  with  Article  10(3)  of  Council  Directive  No.  92/27/EE,  a 
notification of a change to an aspect of the Package Leaflet not connected to the Summary of 
Product  Characteristics.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  29 
October 1998 that the change is accepted. The Commission Decision amending the Community 
Marketing Authorisation was adopted on 22 December 1998. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for  a Type I  variation relating to  an  extension  of  shelf-life of the finished product 
from 24 months to 36 months at 2 – 8 ˚C. The EMEA notified the European Commission and 
the  MAH  on  6  November  1998  that  the  variation  is  accepted.  The  Commission  Decision 
amending the Community Marketing Authorisation was adopted on 26 January 1999. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application  for  a  Type  I  variation  relating  to  a  new  subcontracted  packaging  site  located  in 
Mayenne,  France.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  31 
December 1998 that the variation is accepted. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for a Type I variation relating to the introduction of a new HAB in-house reference 
vaccine. The EMEA adopted a positive opinion on 25 March 1999 and no amendments to the 
Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application  for  a  Type  I  variation  to  replace  of  the  pre-filled  glass  syringe  with  one  which 
consists  of  a  longer  barrel  and  a  longer  plunger  rod.  The  EMEA  notified  the  European 
Commission and the MAH on 24 June 1999 that the variation is accepted. 
1/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission 
Regulation (EC) No. 542/95 for the the scale up of the hepatitis B component of Twinrix Adult. 
The EMEA adopted a positive opinion on 29 July 1999 and no amendments to the Annexes of 
the Community Marketing Authorisation were required. 
The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission 
Regulation (EC) No. 542/95 for the to the implementation of a new working seed for hepatitis B 
component  of Twinrix Adult. The  EMEA adopted  a positive opinion  on  29 July 1999 and no 
amendments to the Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an 
application for a Type I variation for an additional packaging site located in Germany (Bönen), 
in addition to the packaging sites located in Belgium (Rixenart, Wavre) and France (Mayenne). 
The EMEA notified the European Commission and the MAH on 31 May 2000 that the variation 
is accepted. 
The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission 
Regulation  (EC)  No.  542/95  relating  to  a  change  in  the  HBsAg  specifications  and  analytical 
methods.  The  EMEA  adopted  a  positive  opinion  on  29  June  2000  and  no  amendments  to  the 
Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission 
Regulation  (EC)  No.  542/95  for  the  scale-up  of  the  manufacture  of  the  active  substance, 
inactivated  hepatitis  A  virus  (HAV),  which  is  one  of  the  active  substances  of  Twinrix  Adult. 
The  EMEA  adopted  a  positive  opinion  on  21  September  2000  and  no  amendments  to  the 
Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  an  application  for  a  Type  II  variation  in  accordance  with  Commission 
Regulation  (EC)  No.  542/95  to  add  the  wording  regarding  sensitization  to  thiomersal  in 
medicinal products as agreed by CPMP in July 1999 in section 4.4 of SPC. The EMEA adopted 
a positive opinion on 19 October 2000 and the amendments to Annexes I and IIIB (Summary of 
Product Characteristics and Package Leaflet) of the Community Marketing Authorisation were 
adopted on 13 March 2001.  
The  MAH  submitted  an  application  for  a  Type  II  variation  in  accordance  with  Commission 
Regulation (EC) No. 542/95 for the to the approval of a new MRC-5 Manufacturers Working 
Cell Bank, in replacement of the currently used MRC-5 Manufacturer Working Cell Bank, for 
the production of inactivated hepatitis A virus bulk antigen, which is used for the formulation of 
Twinrix  vaccines.  The  EMEA  adopted  a  positive  opinion  on  14  December  2000  and  no 
amendments to the Annexes of the Community Marketing Authorisation were required. 
The  MAH  submitted  in  accordance  with  Article  10(3)  of  Council  Directive  No.  92/27/EE,  a 
notification of a change to an aspect of the Package Leaflet not connected to the Summary of 
Product  Characteristics.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  20 
March 2001 that the change is accepted. The Commission Decision amending the Community 
Marketing Authorisation was adopted on 17 May 2001. 
2/3 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Quality change (demonstration of TSE compliance) 
Update of the SPC  (sections 4.2 and 5.1) following a new 
vaccination schedule  
Renewal 
Change in name of manufacturing site 
Change in the name of the MAH and manufacturer responsible for 
batch release 
Change in name of manufacturing site 
Update of the SPC (section 4.8 undesirable effects) following a 
review of the post-marketing surveillance data. (7th PSUR). 
Change(s) to test methods and/or specifications for the finished 
product 
Amendment of  the Package Leaflet to reflect changes in section 4.8 
of the SPC, previously approved through the variation 
EMEA/H/C/112/II/24. In addition, the name and address of the local 
representatives in Greece, Spain, Italy, Norway and the United 
Kingdom have been updated. 
Change(s) to manufacturing process for the active substance 
Change(s) to shelf-life of the active substance 
Change(s) to test methods and/or specifications for the active 
substance 
Change(s) to test methods and/or specifications for the finished 
product 
Change(s) to manufacturing process for the active substance 
Change(s) to manufacturing process for the active substance 
Addition of a manufacturing site for part of the manufacturing 
process 
The MAH proposes to amend section 4.4 (Special warnings and 
special precaution of use) of the Summary of Product Characteristics 
(SPC) to reflect the factors that may lead to a reduced hepatitis B 
immunogenicity.  The PL has been amended accordingly. In 
addition, the contacts of the DE, ES, IR, PT and FI local 
representatives have been amended. 
II/0018 
II/0019 
R/0020 
I/0021 
I/0022 
I/0023 
II/0024 
II/0025 
II/0026 
II/0027 
II/0028 
II/0030 
II/0031 
II/0032 
II/33 
I/35 
II/0036 
II 
II 
R 
I 
I 
I 
II 
II 
II 
II 
II 
II 
II 
II 
II 
I 
II 
Commission 
Decision 
Issued/amen
ded on 
20.10.01 
30.08.01 
09.11.01 
- 
17.12.01 
- 
11.04.02 
20.09.01 
26.04.01 
26.07.01 
16.11.01 
05.11.01 
16.11.01 
17.01.02 
21.03.02 
03.04.02 
27.06.02 
24.10.02 
25.07.02 
25.07.02 
20.02.03 
02.09.02 
02.09.02 
07.03.03 
25.09.03 
03.10.03 
22.10.03 
22.10.03 
18.07.03 
27.10.03 
27.10.03 
- 
20.11.03 
30.01.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers 
to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a 
minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an 
Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 
March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA 
Notification date. The Commission Decision will be amended accordingly. 
3/3 
EMEA 2005 
 
 
 
 
 
 
 
 
                                                      
 
